Anti-Retroviral Protease Inhibitors Regulate Human Papillomavirus 16 Infection of Primary Oral and Cervical Epithelium.
Samina AlamSreejata ChatterjeeSa Do KangJanice MiliciJennifer BiryukovHan ChenCraig MeyersPublished in: Cancers (2020)
Epidemiology studies suggest that Human Immunodeficiency Virus (HIV)-infected patients on highly active anti-retroviral therapy (HAART) may be at increased risk of acquiring opportunistic Human Papillomavirus (HPV) infections and developing oral and cervical cancers. Effective HAART usage has improved survival but increased the risk for HPV-associated cancers. In this manuscript, we report that Protease Inhibitors (PI) treatment of three-dimensional tissues derived from primary human gingiva and cervical epithelial cells compromised cell-cell junctions within stratified epithelium and enhanced paracellular permeability of HPV16 to the basal layer for infection, culminating in de novo biosynthesis of progeny HPV16 as determined using 5-Bromo-2'-deoxyuridine (BrdU) labeling of newly synthesized genomes. We propose that HAART/PI represent a novel class of co-factors that modulate HPV infection of the target epithelium. Our in vitro tissue culture model is an important tool to study the mechanistic role of anti-retroviral drugs in promoting HPV infections in HAART-naïve primary epithelium. Changes in subsequent viral load could promote new infections, create HPV reservoirs that increase virus persistence, and increase the risk of oral and cervical cancer development in HIV-positive patients undergoing long-term HAART treatment.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- human immunodeficiency virus
- high grade
- hiv positive
- hiv infected
- cervical cancer screening
- patients undergoing
- endothelial cells
- hiv aids
- single cell
- hepatitis c virus
- men who have sex with men
- gene expression
- cell therapy
- stem cells
- south africa
- risk factors
- combination therapy
- replacement therapy
- bone marrow